Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1991 Oct;46(10):717–721. doi: 10.1136/thx.46.10.717

Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.

S H Thomas 1, M J O'Doherty 1, A Graham 1, C J Page 1, P Blower 1, D M Geddes 1, T O Nunan 1
PMCID: PMC463390  PMID: 1750018

Abstract

BACKGROUND Preliminary evidence suggests that regular inhalation of nebulised amiloride reduces sputum viscoelasticity, increases the clearance of sputum by mucociliary mechanisms and by coughing and reduces the rate of deterioration in lung function in patients with cystic fibrosis. These effects depend on adequate delivery of amiloride to the airways. This study was performed to quantify and compare pulmonary deposition of amiloride produced by two different nebuliser systems. METHODS The pulmonary deposition of nebulised amiloride (1 mg in 3 ml saline) was measured in eight patients with cystic fibrosis when given via a jet (System 22 with CR 60 compressor) and an ultrasonic (Fisoneb) nebuliser. Human serum albumin labelled with technectium-99m was used as an indirect marker for amiloride and its deposition in the lung was detected with a gamma camera. RESULTS Amiloride inhalation caused no side effects or changes in spirometric indices. The mean (SD) total pulmonary amiloride deposition was 57 (24) micrograms with the System 22 and 103 (53) micrograms with the Fisoneb nebuliser. Pulmonary deposition was completed more rapidly with the Fisoneb (4-5 minutes) than with the System 22 nebuliser (7-8 minutes) and the Fisoneb was preferred by the patients. CONCLUSIONS Both nebulisers appeared to deliver adequate amounts of amiloride to the lungs, but treatment with the Fisoneb nebuliser was quicker, more efficient, and more acceptable to the patients. Of the two nebulisers assessed, the Fisoneb would be preferred for clinical trials.

Full text

PDF
717

Images in this article

719Image
on p.719

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson P. O., Secker-Walker R. H., Stominger D. B., Markham J., Hill R. L. Pulmonary deposition of aerosols in children with cystic fibrosis. J Pediatr. 1974 Apr;84(4):479–484. doi: 10.1016/s0022-3476(74)80664-5. [DOI] [PubMed] [Google Scholar]
  2. App E. M., King M., Helfesrieder R., Köhler D., Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis. 1990 Mar;141(3):605–612. doi: 10.1164/ajrccm/141.3.605. [DOI] [PubMed] [Google Scholar]
  3. Boucher R. C., Cotton C. U., Gatzy J. T., Knowles M. R., Yankaskas J. R. Evidence for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary cell cultures. J Physiol. 1988 Nov;405:77–103. doi: 10.1113/jphysiol.1988.sp017322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boucher R. C., James M. K., Friedman M., Fullton J., Pimmel R., Gatzy J. T. Acute cardiovascular and pulmonary effects of intravenous and aerosolized amiloride in the dog. Toxicol Appl Pharmacol. 1987 Feb;87(2):264–275. doi: 10.1016/0041-008x(87)90288-2. [DOI] [PubMed] [Google Scholar]
  5. Clarke S. W. Inhaler therapy. Q J Med. 1988 May;67(253):355–368. [PubMed] [Google Scholar]
  6. Elborn J. S., Shale D. J. Cystic fibrosis. 2. Lung injury in cystic fibrosis. Thorax. 1990 Dec;45(12):970–973. doi: 10.1136/thx.45.12.970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ilowite J. S., Gorvoy J. D., Smaldone G. C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987 Dec;136(6):1445–1449. doi: 10.1164/ajrccm/136.6.1445. [DOI] [PubMed] [Google Scholar]
  8. Knowles M. R., Church N. L., Waltner W. E., Yankaskas J. R., Gilligan P., King M., Edwards L. J., Helms R. W., Boucher R. C. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med. 1990 Apr 26;322(17):1189–1194. doi: 10.1056/NEJM199004263221704. [DOI] [PubMed] [Google Scholar]
  9. Knowles M., Gatzy J., Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med. 1981 Dec 17;305(25):1489–1495. doi: 10.1056/NEJM198112173052502. [DOI] [PubMed] [Google Scholar]
  10. Knowles M., Murray G., Shallal J., Askin F., Ranga V., Gatzy J., Boucher R. Bioelectric properties and ion flow across excised human bronchi. J Appl Physiol Respir Environ Exerc Physiol. 1984 Apr;56(4):868–877. doi: 10.1152/jappl.1984.56.4.868. [DOI] [PubMed] [Google Scholar]
  11. Mentz W. M., Brown J. B., Friedman M., Stutts M. J., Gatzy J. T., Boucher R. C. Deposition, clearance, and effects of aerosolized amiloride in sheep airways. Am Rev Respir Dis. 1986 Nov;134(5):938–943. doi: 10.1164/arrd.1986.134.5.938. [DOI] [PubMed] [Google Scholar]
  12. Newman S. P., Woodman G., Clarke S. W. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax. 1988 Apr;43(4):318–322. doi: 10.1136/thx.43.4.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. O'Doherty M. J., Thomas S., Page C., Barlow D., Bradbeer C., Nunan T. O., Bateman N. T. Differences in relative efficiency of nebulisers for pentamidine administration. Lancet. 1988 Dec 3;2(8623):1283–1286. doi: 10.1016/s0140-6736(88)92894-2. [DOI] [PubMed] [Google Scholar]
  14. O'Doherty M., Thomas S., Page C., Bradbeer C., Nunan T., Bateman N. Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill. Thorax. 1990 Jun;45(6):460–464. doi: 10.1136/thx.45.6.460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Potter J. L., Matthews L. W., Spector S., Lemm J. Studies on pulmonary secretions. II. Osmolality and the ionic environment of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis. 1967 Jul;96(1):83–87. doi: 10.1164/arrd.1967.96.1.83. [DOI] [PubMed] [Google Scholar]
  16. Ruffin R. E., Dolovich M. B., Wolff R. K., Newhouse M. T. The effects of preferential deposition of histamine in the human airway. Am Rev Respir Dis. 1978 Mar;117(3):485–492. doi: 10.1164/arrd.1978.117.3.485. [DOI] [PubMed] [Google Scholar]
  17. Schoeffel R. E., Anderson S. D., Altounyan R. E. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. Br Med J (Clin Res Ed) 1981 Nov 14;283(6302):1285–1287. doi: 10.1136/bmj.283.6302.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Secker-Walker R. H., Hill R. I., Markham J., Baker J., Wilhelm J., Alderson P. O., Potchen E. J. The measurement of regional ventilation in man: a new method of quantitation. J Nucl Med. 1973 Oct;14(10):725–732. [PubMed] [Google Scholar]
  19. Thomas S. H., O'Doherty M. J., Page C. J., Nunan T. O., Bateman N. T. Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers. Eur Respir J. 1991 May;4(5):616–622. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES